Skip to content Skip to footer

Ventus Therapeutics Partners with Genentech to Develop Small-Molecule Drugs Using ReSOLVE Platform

Shots:Ventus Therapeutics has entered a multi-year collaboration with Genentech to discover and optimize novel small-molecule drugs for major diseases using its ReSOLVE platformAs per the deal, Ventus will utilize its ReSOLVE platform to identify small-molecule leads for multiple targets, while Genentech will be responsible for preclinical, clinical, and commercial development. Ventus will receive…

Read more

Viewpoints_Kasper Roet 

Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots

Shots: Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds. QurAlis received an up front payment of $45M plus an additional equity investment. The company is…

Read more